Pharma's New Worldview: Transforming R&d Through Emerging Markets
- Tags:
- Business Operations,
- Emerging Market,
- Offshore,
- Pharmaceutical Company,
- R&D,
- Research & Development
- Source:
- IBM
FREE Registration is required
Overview: Like other industries, big Pharma has grown comfortable with certain offshore capabilities, such as manufacturing. But because they consider R&D such a defining capability, pharma companies have generally been hesitant to move R&D activities outside the firm - much less offshore. Squeezed by shareholder and payer demands, these companies are now reevaluating that position and considering the possibility of performing selected R&D activities offshore. From IBM's review of the pharmaceutical sector, however, it appears that offshore R&D remains a relatively untapped opportunity - one that big Pharma may not be prepared to exploit fully. Pharma's R&D business models are still skewed toward a developed markets perspective - witness how often research priorities are focused on the needs of developed nations and in-licensing opportunities from developed markets take precedence.
(Is this item miscategorized? Does it need more tags? Let us know.)
Format: PDF | Size: 264KB | Date: Sep 2006 | Pages: 20
